Powerful bactericidal activity of moxifloxacin in human leprosy

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3113-3117

  Pardillo, Fe Eleanor F ^a   Burgos, Jasmin ^a   Fajardo, Tranquilino T ^a   Dela Cruz, Eduardo ^a   Abalos, Rodolfo M ^a   Paredes, Rose Maria D ^a   Andaya, Cora Evelyn S ^a   Gelber, Robert H ^a,b  

^a Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

^b Leonard Wood Memorial Research Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; MOXIFLOXACIN; RIFAMPICIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; EPIGASTRIC PAIN; ERYTHEMA NODOSUM LEPROSUM; HEMATOCRIT; HUMAN; LEPROSY; MALE; MYCOBACTERIUM LEPRAE; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; SKIN DEFECT; TREATMENT DURATION;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; FOOT; HUMANS; LEPROSY; MALE; MICE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; QUINOLINES; SKIN; TREATMENT OUTCOME;

EID: 50949086971     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01162-07     Document Type: Article

References (37)

1. Blumberg, H. M., W. J. Burman, R. E. Chaisson, C. L. Daley, S. C. Etkind, L. N. Friedman, P. Fujiwara, M. Grzemska, P. C. Hopewell, M. D. Iseman, R. M. Jasmer, V. R. Koppaka, R. I. Menzies, R. J. O'Brien, R. R. Reves, L. B. Reichman, P. M. Simone, J. R. Starke, and A. A. Vernon. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
2. Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, and R. E. Chaisson. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
3. Chan, G. P., B. Y. Garcia-Ignacio, V. E. Chavez, J. B. Livelo, C. L. Jimenez, M. L. R. Parilla, and S. G. Franzblau. 1994. Clinical trial of clarithromycin for lepromatous leprosy. Antimicrob. Agents Chemother. 38:515-517.
4. Choi, J. H., M. J. Song, S. H. Kim, S. M. Choi, D. G. Lee, J. H. Yoo, and W. S. Shin. 2003. Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 47:3704-3707.
5. Consigny, S., A. Bentoucha, B. Pascale, J. Grosset, and B. Ji. 2000. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob. Agents Chemother. 44:2919-2921.
6. Dong, Y., X. Chen, X. Zhao, J. Domagala, and K. Drlica. 1998. Fluoroquinolone action against mycobacteria: effect of C-8 substituents on growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984.
7. East African/British Medical Research Council. 1974. Controlled clinical trail of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet ii:110-1106.
8. Fajardo, T. T., Jr., L. G. Villahermosa, E. C. Dela Cruz, R. M. Abalos, S. G. Frazblau, and G. P. Walsh. 1995. Minocycline in lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis. 63:8-17.
9. Fajardo, T. T., Jr., L. G. Villahermosa, E. C. Dela Cruz, R. V. Cellona, M. V. Balagon, R. M. Abalos, and R. H. Gelber. 2005. A clinical trial of pefioxacin and ofloxacin in lepromatous leprosy. Lepr. Rev. 73:389-391.
10. Gelber, R. H. 1994. Chemotherapy of lepromatous leprosy: recent developments and prospects for the future. Eur. J. Clin. Microbiol. Infect. Dis. 13:942-952.
11. Gelber, R. H., V. F. Balagon, and R. V. Cellona. 2004. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int. J. Lepr. Other Mycobact. Dis. Vol. 72:493-500.
12. Gelber, R. H., K. Fukuda, S. Byrd, L. P. Murray, P. Siu, M. Tsang, and T. H. Rea. 1992. A clinical trial of minocycline in lepromatous leprosy. Br. Med. J. 304:91-92.
13. Gelber, R. H., A. Iranmanesh, L. Murray, P. Siu, and M. Tsang. 1992. Activities of various quinolone antibiotics against Mycobacterium leprae in infected mice. Antimicrob. Agents Chemother. 36:2544-2547.
14. Gillespie, S. H., and O. Billington. 1999. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 44:393-395.
15. Gillespie, S. H., R. D. Gosling, L. Uiso, N. E. Sam, E. G. Kaduma, and T. D. McHugh. 2005. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J. Antimicrob. Chemother. 56:1169-1171.
16. Girdhar, B. K., A. Girdhar, and A. Kumar. 2000. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr. Rev. 71:144-153.
17. Gosling, R. D., L. O. Uiso, N. E. Sam, E. Bongard, E. G. Kanduma, M. Nyindo, R. W. Morris, and S. H. Gillespie. 2003. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 168:1342-1345.
18. Grosset, J. H., C. C. Guelpa-Lauras, E. G. Perani, and C. Beoletto. 1988. Activity of ofloxacin against Mycobacterium leprae in the mouse. Int. J. Lepr. Other Mycobact. Dis. 56:259-264.
19. Grosset, J. H., B. Ji, C. C. Guelpa-Lauras, E. G. Perani, and L. N'Deli. 1990. Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis. 58:281-295.
20. Guelpa-Lauras, C. C., E. G. Perani, A. M. Giroir, and T. H. Grosset. 1987. Activity of pefloxacin and ciprofloxacin against Mycobacterium leprae in the mouse. Int. J. Lepr. Other Mycobact. Dis. 55:70-77.
21. Hong Kong Chest Service/British Medical Research Council. 1978. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Am. Rev. Respir. Dis. 118:219-227.
22. Jamet, P., B. Ji, et al. 1995. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Int. J. Lepr. Other Mycobact. Dis. 63:195-201.
23. Ji, B., N. Lounis, C. Maslo, C. Truffot-Pernot, P. Bonnafous, and J. Grosset. 1998. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium teuberculosis. Antimicrob. Agents. Chemother. 42:2066-2069.
24. Johnson, J., D. Hadad, W. Boom, C. Daley, C. Peloquin, K. Eisenach, D. Jankus, S. Debanne, E. Charlebois, E. Maciel, et al. 2006. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 10:605-612.
25. Miyazaki, E., M. Miyazaki, J. M. Chen, R. E. Chaisson, and W. R. Bishai. 1999. Moxifloxacin (BAY12-8039), a new 8-methoxquinolone, is active in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 43:85-89.
26. N'Deli, L., C. C. Guelpa-Lauras, E. G. Perani, and J. H. Grosset. 1990. Effectiveness of pefloxacin in the treatment of lepromatous leprosy. Int. J. Lepr. Other Mycobact. Dis. 58:23-28.
27. Nuennberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. OBrien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169:521-426.
28. Pletz, M. W., A. De Roux, A. Roth, K. H. Neumann, H. Mauch, and H. Lode. 2004. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob. Agents Chemother. 48:780-782.
29. Rees, R. J. W., J. M. H. Pearson, and M. F. R. Waters. 1970. Experimental and clinical studies on rifampicin in treatment of leprosy. Br. Med. J. 1:89-92.
30. Ridley, D. S., and W. H. Jopling. 1966. Classification of leprosy according to immunity: a five-group system. Int. J. Lepr. Other Mycobact. Dis. 34:255-273.
31. Saito, H., H. Tomioka, and K. Nagashima. 1986. In vitro and in vivo activity of ofloxacin against Mycobacterium leprae infection induced in mice. Int. J. Lepr. Other Mycobact. Dis. 54:560-562.
32. Shepard, C. C. 1981. A brief review of experiences with short-term clinical trials monitored by mouse-foot-pad-inoculation. Lepr. Rev. 52:299-308.
33. Shepard, C. C. 1982. Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. Int. J. Lepr. Other Mycobact. Dis. 50:96-101.
34. Shepard, C. C., L. Levy, and P. Fasal. 1972. Rapid bactericidal effect of rifampicin on Mycobacterium leprae. Am. J. Trop. Med. Hyg. 21:446-449.
35. Weiss, T., I. Shalit, H. Blau, S. Werber, D. Halperin, A. Levitov, and I. Fabian. 2004. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-κ and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob. Agents Chemother. 48:1974-1982.
36. World Health Organization. 1982. Chemotherapy of leprosy for control programmes. WHO Tech. Rep. Ser. 675:1-33.
37. World Health Organization. 1998. World Health Organization expert committee on leprosy. WHO Tech. Rep. Ser. 874:1-43.